BioNeutral Elects Stephen Holt, M.D., Ph.D as Vice Chairman and Independent Director of the Board
NEWARK, N.J., March 25, 2011 /PRNewswire/ -- BioNeutral Group, Inc. (OTC Bulletin Board: BONU), a specialty life science technology-based company, today announced the appointment of Dr. Stephen Holt, M.D., Ph.D, a Distinguished Professor of Medicine (Emeritus) and a medical practitioner in New York State, as the Company's Vice Chairman of the Board and Independent Director. Dr. Holt is an independent consultant to the pharmaceutical and dietary supplement industry, and a Board-certified Internist and Sub-Specialist in the United States, Canada, United Kingdom and European Union.
"We are extremely pleased to welcome Dr. Holt to our Board. He is an esteemed member of the medical community and has established relationships with healthcare facilities worldwide. As an added benefit, his experience in the medical community can help us accelerate the commercialization of our recent EPA-approved Hospital-Grade Ygiene® ," said Stephen J. Browand, Chairman and CEO of BioNeutral Group, Inc. "The addition of Dr. Holt also increases the number of independent directors to our Board, which is in line with our commitment to increase transparency and adhere to the highest levels of corporate governance."
Dr. Holt is currently a Consultant Physician in Gastroenterology, Medicine and Nutrition, New York; and a Board member of Integrative Medicine Asia; Global Foundation of Integrative Medicine; and the European Society of Anti-Aging Medicine. Dr. Holt has published many peer-review papers in medicine and is a best-selling author with twenty books in national and international distribution. Dr. Holt is a frequent lecturer at scientific meetings and healthcare facilities throughout the world. He is the founder of the Holt Institute of Medicine and Lieutenant Grand Hospitaller of the Holy Order of the Sovereign Knights of St. John of Jerusalem. Dr. Holt is an Honors Graduate of Liverpool University Medical School, England.
About BioNeutral Group, Inc.
Headquartered at the New Jersey Institute of Technology/EDC in Newark, BioNeutral Group, Inc., is a specialty technology-based life science company which has developed a technology platform that neutralizes harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores. BioNeutral's products, Ygiene® and Ogiene®, kill germs and clean surfaces with a dramatic increase in speed and power over their rivals in the marketplace. BioNeutral's proprietary platform technology has been proven effective in surface, water and airborne applications. Its antimicrobial line of products under the Ygiene® brand have been approved by the EPA for sale in the United States and has previously been approved for sale in Germany and it is also permitted to be sold in the UK, France and Sweden. AutoNeutral is a Registered trademark of BioNeutral Group, Inc. For more information on BioNeutral, including a listing of company products, leadership and background please visit www.bioneutralgroup.com.
Find us on Facebook: http://www.facebook.com/pages/BioNeutral-Group/149109938452393
Follow us on Twitter: http://twitter.com/bioneutralgroup
This release contains certain "forward-looking statements" relating to the business of the Company and its subsidiary companies. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions. Such forward looking statements involve known and unknown risks and uncertainties that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those described in the Company's filings with the Securities and Exchange Commission. BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how the Company's technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA has approved and registered the Company's data and findings specific to Ygiene®-206 BioNeutral's antimicrobial formulations will be marketed under the brand name Ygiene® and will soon be available for sale in the United States.
North 6th Agency
Investor Relations Contact:
ProActive Capital Resources Group, LLC
FOR THE COMPANY:
Stephen J. Browand
BioNeutral Group, Inc.
SOURCE BioNeutral Group, Inc.